Thompson Davis & CO. Inc. Sells 7,244 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Thompson Davis & CO. Inc. cut its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 33.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,600 shares of the company’s stock after selling 7,244 shares during the quarter. Thompson Davis & CO. Inc. owned approximately 0.05% of GeneDx worth $620,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of WGS. Oracle Investment Management Inc. boosted its stake in GeneDx by 531.7% in the 1st quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock valued at $10,286,000 after purchasing an additional 948,253 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of GeneDx during the second quarter worth $11,335,000. Assenagon Asset Management S.A. bought a new stake in shares of GeneDx in the second quarter valued at about $9,575,000. Divisadero Street Capital Management LP acquired a new position in shares of GeneDx in the second quarter valued at about $5,886,000. Finally, Millennium Management LLC increased its position in GeneDx by 193.5% during the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock worth $8,140,000 after acquiring an additional 205,318 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Down 0.1 %

NASDAQ WGS opened at $71.04 on Wednesday. The business has a fifty day moving average price of $57.43 and a two-hundred day moving average price of $38.69. The stock has a market capitalization of $1.95 billion, a PE ratio of -22.84 and a beta of 2.11. GeneDx Holdings Corp. has a fifty-two week low of $1.29 and a fifty-two week high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period in the prior year, the company earned ($0.82) EPS. GeneDx’s revenue for the quarter was up 44.3% on a year-over-year basis. Equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder School Of Medicine At Mo Icahn sold 865,800 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total transaction of $64,935,000.00. Following the sale, the insider now owns 2,866,833 shares of the company’s stock, valued at $215,012,475. This trade represents a 23.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 23,108 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84. Following the completion of the transaction, the chief executive officer now directly owns 82,318 shares of the company’s stock, valued at approximately $5,801,772.64. The trade was a 21.92 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,065,580 shares of company stock worth $78,848,138. Corporate insiders own 27.30% of the company’s stock.

Wall Street Analyst Weigh In

WGS has been the subject of a number of recent research reports. Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. BTIG Research raised their price objective on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Finally, TD Cowen increased their target price on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.